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S U M M A R Y
Objectives: To review the current literature on mucormycosis in immunocompentent/otherwise healthy
individuals, to which ﬁve new cases with maxillary sinus involvement have been added.
Methods: We searched in the PudMed database all articles in the English language related to human
infections caused by fungi of the order Mucorales, in immunocompetent/otherwise healthy patients,
starting from January 1978 to June 2009. In addition, we updated the literature by reporting ﬁve new
cases diagnosed and treated at the oral medicine unit of our institution.
Results: The literature review showed at least 126 articles published from 35 different countries in the
world, to a total of 212 patients described. The most affected country was India with 94 (44.3%) patients
and the most representative clinical form was the cutaneous/subcutaneous with 90 (42.5%) patients. Our
ﬁve immunocompetent patients with a diagnosed infection of Mucorales localized at the maxillary sinus
completely healed with lyposomial amphotericin B.
Conclusions: The literature analysis revealed that even in immunocompetent/otherwise healthy
individuals mucormycosis infection has a worldwide distribution. What might be the real predisposing
factors involved in its pathogenesis in such patients and the real causes of this peculiar geographic
distribution still remains unknown. It is likely that, in our cases, a chronic insult of a well-deﬁned and
localized body area might have resulted in a local immunocompromission, thus fostering the
development of an invasive fungal infection.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Mucormycosis is a rare opportunistic infection, which repre-
sents the third most common angio-invasive fungal infection after
candidiasis and aspergillosis and is considered as one of the most
important medical complications in immunocompromised
patients.1,2 Even though it is extremely rare, it has been reported
from all corners of the world.3
The majority of patients developing mucormycosis reported
having history of risk factors. The most common risk factors for
mucormycosis are summarized in Table 1.3–5
The increase in the number of cases of invasive mucormycosis is
attributable to the recent rise of cancer incidence, the resistance to* Corresponding author at: Oral Medicine Unit Department of Odontostomato-
logical and Maxillofacial Sciences Federico II University of Naples Via Pansini 5,
80131 Naples, Italy. Tel.: +39 817462498; fax: +39 817462197.
E-mail address: mignogna@unina.it (M.D. Mignogna).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.02.005the commonly used antifungal agents and immunosuppressive
therapies, including organ transplantations, which result in
growing of highly immunocompromised population,1,2,4 although,
in the last 30 years, several cases of mucormycosis in immuno-
competent/otherwise healthy individuals have been described.5–
130 Also, some patients with mucormycosis have no identiﬁable
risk factors.131
Management of mucormycosis still represents a big challenge
and is based on different strategies which envisage a rapid
diagnosis, removal or reduction of risk factors (drugs or underlying
diseases), rapid and aggressive antifungal infection (polyenes)
with or without surgical debridment, and, lastly, with adjuvant
therapies in patients refractory or intolerant to polyene-based
therapy (posaconazole, deferasirox plus lipid polyenes, recombi-
nant cytokines granulocyte colony-stimulating factor, granulocyte
macrophage colony-stimulating factor, or interferon-g, hyperbaric
oxygen).132 The main purpose of this review is to report data over
the last 30 years about the percentage of immunocompentent/
otherwise healthy individuals suffering from mucormycosis, of theses. Published by Elsevier Ltd. All rights reserved.
Table 1
Main risk factors for the development of mucormycosis in humans5–130
Underlying disease Therapy Transplantation Local conditions General conditions
Leukemia Antineoplastic agents Solid organ Burns Malnutrition
Lymphoma Corticosteroids Bone marrow Trauma
Multiple myeloma Antibiotics Peripheral blood stem cell
Neutropenia Antirejection agents
Matabolic disorder (Diabetes type I and II)
with or without ketoacidosis
Intravenous drug abuse
Cirrhosis Radiation
Acute renal failure Deferoxamine
M.D. Mignogna et al. / International Journal of Infectious Diseases 15 (2011) e533–e540e534most common form, and the most affected country, as no similar
data are currently available in the literature. The secondary
outcome was to update the current literature adding ﬁve new cases
of mucormycosis in immunocompetent patients, referred to and
treated by our institution, who developed the disease following a
chronic localized inﬂammation, and discuss the likely underlying
pathogenetic mechanism.
2. Patients and Methods
We retrospectively reviewed all human infections caused by
fungi of the order Mucorales, by searching in the PudMed database
each of the following Key words: ‘‘Mucormycosis; Zygomycosis;
Phycomycosis; Mucor racemosus; Mucor circinelloides; Mucor
ramosissimus; Mucor indicus; Mucor hiemalis; Rizopus arrhizus;
Rizopus oryzae; Rizopus rhizopodiformis; Rizopus azygosporus;
Rizopus stolonifer; Rizopus schiperrae; Rizopus microsporus micro-
sporus; Rizopus microsporus rizhopodiformis; Rizopus microsporus
oligosporus; Rhizomucor pusillus; Absidia corymbifera; Mycocladus
corymbifer; Apophysomyces elegans; Cunninghamella bertholletiae;
Saksenaea vasiformis; Cokeromyces recurvatus’’ in association with
‘‘healthy’’ and ‘‘immunocompetent’’ alternatively.
The inclusion criteria of this review encompass: 1) articles in
the English language published between January 1978 and June
2009, reporting the clinical form of mucormycosis for all patients
described; 2) healthy or immunocompetent patients who con-
tracted an infection of the order Mucorales between January 1978
and June 2009; 3) absence of any predisposing risk factors in the
present or past medical history, except for local conditions (Table
1); 4) absence of any previous underlying diseases to the diagnosis
of mucormycosis; 5) documentation of Mucor infection either
histologically or by culture. We also included cases of pregnant
women and drug-addicted or alcoholic patients.
Of the overall reviewed articles we collected, tabulated, and
depicted the following information: number of patients reported
in each article, clinical manifestations of mucormycosis, place of
origin.
Fisher’s exact test, Odds Ratio (OR) and 95% conﬁdence interval
(CI) were calculated comparing the cutaneous/subcutaneous form
with all the other forms, and India with all the other countries in
the world. Statistical analysis was performed using GraphPad 5.0
(Prism 5.0, GraphPad Software, Inc., San Diego, CA).
Commonly, clinical manifestations of mucormycosis are
classiﬁed in: 1) rhino-orbito-cerebral, 2) disseminated/miscella-
neous, 3) cutaneous/subcutaneous, 4) gastrointestinal, 5) pulmo-
nary, and 6) uncommon presentations.133 For the sake of brevity,
we grouped the category of either isolated cerebral or isolated
rhino-cerebral or isolated sinuso-orbital or isolated maxillary
(sinusal) or isolated orbital mucormycosis into rhino-orbito-
cerebral mucormycosis.
In order to update the current literature on this topic, we also
report ﬁve new cases (4 men and 1 woman) with a history of
chronic sinusitis were admitted for evaluation of aggravation of a
cohort of long-lasting and debilitating related symptoms (Table 2),diagnosed and treated at the Oral Medicine Unit, Federico II
University of Naples, Italy, between 2003 and 2008.
All patients, after providing their written informed consent,
were hospitalized and examined by a head and neck CT scan, and
complete laboratory work-up. For a thorough evaluation, they
were also referred to the nearby othorhynoloaringological (ORL)
unit, where a biopsy of sinusal mucosa was taken via a rigid nasal
endoscopy. A diagnosis of mucormycosis was established, based on
the clinical, radiological, and histopathological criteria. Invasion
seen on histopathology was needed to conﬁrm a diagnosis.
In order to evaluate the extent of the disease, they underwent a
total body computed tomography (CT) scan, an electrocardiogram,
and serum tumor markers
All patients received the same treatment protocol that has
consisted in an adequate hydration and a premedication with
acetaminophen (500 mg qd PO), chlorpheniramine (20 mg daily,
intravenous) and methylprednisolone (40 mg daily, intravenous),
30 minutes before each infusion. Liposomal amphotericin B
(Ambisome1, Gilead Sciences S.r.l., Milan, Italy) was infused
intravenously by an electronic pumping device (Optima MS,
Fresenius Vial, France) at a total dose of 3 mg/kg/die given over 5
consecutive days. The therapy was adjusted from 5 to 3 mg/kg/die
due to a localized involvement and patients’ immunocompetent
status. The infusion was administered slowly at 70 – 100 mg per
hour. All patients received three cycles of therapy to a total of 15
days of treatment. Vital signs were monitored before, during, and
after each infusion.
After treatment, each patient underwent all the laboratory,
histological, and radiological investigations, in order to ascertain
whether or not a complete healing occurred. Patients were also
regularly followed-up every two months for at least 6 months to
ensure complete resolution of mucormycosis and to detect any
possible relapse.
3. Results
The analysis of literature review revealed at least 126 articles
published between 1978 and 2009, from 35 different countries in the
world, to a total of 212 patients described. The most affected place
was India with 94 (44.3%) patients, followed by USA and Australia
with 42 (19.8%) and 12 (5.7%) patients, respectively (Table 3). Just 6
(2.8%) cases have been described from Italy, to which our 5 new cases
should be added, reaching a total of 11 cases. The higher prevalence
of mucormycosis in India turned out to be statistically signiﬁcant (p
< 0.0001) in comparison with all other countries, from USA (OR:
3.22; CI 95%: 2.09 – 4-97) to Argentina, Belgium, and so on (OR:
168.1; CI 95%: 23.12 – 1222) (Table 4).
The most representative clinical form described in immunocom-
petent/otherwise healthy patients was the cutaneous/subcutaneous
form with 90 (42.5%) patients, followed by the rhino-orbito-cerebral
with 81 (38.2%) patients and genitor-urinary with 18 (8.5%) patients
(Table 3). Even though the cutaneous/subcutaneous form was the
most representative, our analysis revealed that no statistical
difference exists with the rhino-orbito-cerebral form (OR: 1.19; CI
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Table 3
Geographic distribution and clinical forms of mucormycosis in 212 immunocom-
pentent/ otherwise healthy individuals described over the last 30 years
Number of Patients (%)
Country India 94 (44.3)
USA 42 (19.8)
Australia 12 (5.7)
Italy 6 (2.8)
Brazil, Pakistan 5 (2.4)
Venezuela 4 (1.9)
Canada, China,
France, Germany, UK
3 (1.4)
Arabia, Holland,
Japan, Qatar,
South Korea, Spain
2 (0.9)
Argentina, Belgium,
Colombia, Denmark,
Ecuador, Finland,
Greece, Iraq, Ireland,
Israel, Kuwait, Oman,
Sri-Lanka, South Africa,
Swiss, Taiwan, Turkey
1 (0.5)
Forms Cutaneous/subcutaneous 90 (42.5)
Rhino-orbito-cerebral 81 (38.2)
Genitourinary 18 (8.5)
Disseminated 10 (4.7)
Pulmonary 7 (3.3)
Gastrointestinal 5 (2.4)
Vascular 1 (0.5)
Years 2006–09 61 (28.7)
2001–05 72 (33.9)
1996–00 25 (11.7)
1991–95 21 (9.9)
1986–90 18 (8.5)
1981–85 7 (3.3)
1978–80 8 (3.7)
M.D. Mignogna et al. / International Journal of Infectious Diseases 15 (2011) e533–e540 e53595%: 0.80 – 1.76; p= 0.42). Conversely, a signiﬁcant statistical
difference was found with all the remaining clinical forms, form
genitourinary (OR: 7.95; CI 95%: 4.56 – 13.84; p < 0.0001) to vascular
form (OR: 155.7; CI 95%: 21.41 – 1132; p < 0.0001) (Table 5).
Lastly, the majority of patients with mucormycosis have been
reported over the last eight years, with 72 (33.9%) patients
described in the ﬁve-year 2001-2005, and 61 (28.7%) patients in
the three-year 2006-2009 (Table 3).
In our study group, four patients were male and one patient was
female. Their age at the time of diagnosis ranged from 46 to 67
years (mean, 54.5  8.6 years) (Table 2). They were seen 2-4 weeks
after the onset of the following clinical signs and symptoms: fever,
headache, orbital pain, diplopia, rhinorrhea, trigeminal nerve
distribution pain (Table 2).
Intra and extra-oral examination did not reveal any ulcerations
or necrosis. The examination of nasal mucosa of 2 out of 5 patients
showed necrotic tissue with black eschar, whereas nasal endosco-
py in all patients demonstrated a variously inﬂamed sinusal
mucosa with or without the presence of purulent exudates.
In all cases routine blood tests, serum tumor markers and
electrocardiogram did not reveal any abnormalities that could
predispose to invasive fungal infections (IFIs), except for a mild
increase of Fibrinogen at the time of admission in 3 out of 5
patients. Similarly, total body CT scan to evaluate the extension of
the disease was negative in all patients. So, we concluded that
infection was localized at the oro-facial area.
Patients’ characteristics including clinical, radiological, and
therapeutic parameters are summarized in Table 2. Histologically
all cases exhibited numerous broad aseptate fungal hyphae, with a
right-angle branching varying from 45 to 908, consistent with the
morphology of the order Mucorales (Figure 1). There was no chance
in our institution to determine the genus of Mucorales.
Patients had no history of travel or physical trauma or burn. All
patients reported a history of chronic sinusitis of unknown
Table 4
Comparison between India and all other countries in the world (Fisher’s exact test,
p < 0.05).
Country OR CI 95% p-value
USA 3.22 2.09–4.97 < 0.0001
Australia 13.3 6.98–25.25 < 0.0001
Italy 27.35 11.62–64.37 < 0.0001
Brazil, Pakistan 32.98 13.04–83.4 < 0.0001
Venezuela 41.42 14.85–115.6 < 0.0001
Canada, China, France,
Germany, UK
55.5 17.16–179.1 < 0.0001
Arabia, Holland, Japan,
Qatar, South Korea, Spain
83.64 20.24–345.7 < 0.0001
Argentina, Belgium, Colombia,
Denmark, Ecuador, Finland,
Greece, Iraq, Ireland, Israel,
Kuwait, Oman, Sri-Lanka,
South Africa, Swiss,
Taiwan, Turkey
168.1 23.12–1222 < 0.0001
OR, Odds Ratio; CI, Conﬁdence Interval.
Table 5
Comparison between the cutaneous/subcutaneous clinical and all other forms
(Fisher’s exact test, p< 0.05).
Forms OR CI 95% p-value
Rhino-orbito-cerebral 1.19 0.80–1.76 0.42
Genitourinary 7.95 4.56–13.84 < 0.0001
Disseminated 14.9 7.46–29.74 < 0.0001
Pulmonary 21.6 9.69–48.14 < 0.0001
Gastrointestinal 30.54 12.07–77.26 < 0.0001
Vascular 155.7 21.41–1132 < 0.0001
OR, Odds Ratio; CI, Conﬁdence Interval.
Figure 1. (A) Histological analysis showed the presence of broad aseptate fungal
hyphae, with a right–angle branching varying from 45 to 90. (B) Grocott
methenamine–silver staining conﬁrmed the presence of a fungal infection of the
order Mucorales. Specimen isolated from patient 2.
M.D. Mignogna et al. / International Journal of Infectious Diseases 15 (2011) e533–e540e536etiology. Just one patient reported a history of radiotherapy due to
a rhino-pharyngeal cancer occurred 10 years earlier, that might
have made him more susceptible of developing a chronic sinusitis.
No patient presented with any underlying diseases, except one
patient with a very mild benign prostatic hypertrophy, for which
no medical treatment was required (Table 2).
All patients were considered completely healed after the
infusion therapy, based on general criteria for global response to
antifungal therapy in invasive mold disease.134 Indeed, clinical,
radiological, histological, and serological examinations performed
after treatment were negative. The average duration of the follow-
up was 24.8  20.8 months.
4. Discussion
According to the new taxonomic revision of the fungi,135 the
phylum Zygomycota, subphylum Zygomycotina, and class Zygo-
mycetes disappeared in their widely understood sense to be
replaced by the phylum Glomeromycota (for arbuscular mycorrhizal
fungi). Glomeromycota has a subphylum Mucormycotina, which
includes the order Mucorales, which in turn are considered as
etiologic factor of mucormycosis infection. They are characterized
by the production of a coenocytic mycelium and the formation of
asexual spores (sporangiospores) in a variety of fungal structures.136
These opportunistic pathogens are ubiquitous organisms,
existing in the environment, soil, air, food, compost piles, animal
excreta, and play a pivotal role in the cycle of decomposition in the
natural world. Although the majority of these pathogenic fungi
require oxygen, they are capable of growth in anaerobic and
microaerophilic conditions.133,137,138
For many years the term mucormycosis has been interchange-
ably used with zygomycosis in the medical literature.139 Currently,
in line with a recent classiﬁcation,135 we prefer to use the term
mucormycosis rather than zygomycosis.Due to the rarity of this infection, it is difﬁcult to calculate
accurately its incidence. In US the annual incidence of mucormy-
cosis has been estimated as 1.7 infections per million populations,
i.e, approximately 500 cases per year.140 More recently, in tertiary
care hospital at the University Hospitals Leuven, the overall
incidence has been calculated in 0.042 cases per 10,000 patient.141
In transplanted patients, the incidence of mucormycosis ranged
from 0.2 to 1.2% of renal transplants, 0 to 1.6% of liver transplants, 0
to 0.6% of heart transplants, 0 to 1.5% of lung transplants, and 0.9 to
1.9% of allogenic bone marrow transplants.3
Commonly, mucormycosis has shown an equal sex distribution,
although a recent review of all published cases of pulmonary
mucormycosis showed a male-to-female ratio of 3:1.142
Mortality rate is higher than 50% with an incidence ranging
from 62.5% in rhino-cerebral form143 to 100% in disseminated
form.140 Its high morbidity and mortality rates are related to its
capacity for rapidly vascular invasions, with subsequent tissue
necrosis and infarction.133
The overall survival rate of patients with mucormycosis ranges
approximately from 50% to 85% with a higher survival rate of
rhino-cerebral mucormycosis than pulmonary or disseminated
form because the rhinocerebral disease can frequently be
diagnosed earlier, and the most common underlying cause,
diabetic ketoacidosis, can be readily treated.140 Notably, if the
disease has not penetrated beyond the sinus, the prognosis is much
better; indeed, in local sinonasal disease, the mortality has been
reported to be less than 10%.140
Figure 2. (A) Percentage of patients with mucormycosis in 35 different countries;
(B) percentage of patients with each of the seven different clinical forms of
mucormycosis and (C) trends in mucormycosis over the last 30 years in 5-year
increments. Data calculated from 212 immunocompetent/otherwise healthy
patients.
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rhino-orbito-cerebral (44–49%), followed by cutaneous (10–16%),
pulmonary (10–11%), disseminated (6–11.6%) and gastrointestinal
(2–11%) presentations.3
Due to ubiquitous nature of this fungus (excavation, construc-
tion, contaminated air ducts),133 inhalation of sporangiospores
from the atmosphere is the most common route for rhino-orbito-
cerebral and pulmonary infections, whereas the cutaneous form is
usually related to a contamination following physical trauma. The
disseminated and gastrointestinal forms are mainly due to cancer,
transplantations, metabolic diseases, malnutrition, chemo, radio
and/or immunosuppressive therapy.3
In immunocompetent patients, the nose and/or maxillary sinuses
appear to be the predominant source of infection of the respiratory
tract. If sporangiospores are larger than 10 mm, they may remain
localized to the upper airways, giving an isolated form, i.e., sinusal or
rhino form; otherwise they may colonize the distal alveolar spaces
involving the pulmonary tract.3,133 Once infection has colonized
nose and paranasal sinuses, if not promptly diagnosed and treated, it
is likely that, in such patients, this infection may invade the base of
the skull through blood vessels, disseminating to the central nervous
system, giving the rhino-orbito-cerebal form,3 or everywhere in the
body, giving the disseminated form.
As the mucosal/cutaneous epithelium and endothelium repre-
sent a fundamental and effective barrier against tissue invasion
and angioinvasion, it appears that this IFI in immunocompetent/
otherwise healthy patients might be relatively rare. Actually, the
possibility of developing a Mucor infection in such patients seems
to be related to the ability of this fungus of attacking the
epithelium previously damaged by prior infection, cytoxic agent or
direct trauma.133 It is likely that Mucor sporangiospores are also
capable of secreting several toxins or proteases, which may
directly destroy endothelial cells in mucosal membranes.133
We do not know when and how our patients had contracted it.
We may speculate that these fungi might have availed of the
damaged epithelium in order to invade the mucosal sinuses,
spreading along vascular and neuronal structures and inﬁltrating
the walls of blood vessels. Infection would have eroded bone
through walls of the sinus and remained localized, thanks to an
early diagnosis and aggressive systemic treatment; otherwise, it is
assumable that Mucor infection would have spread into the orbit
and the retro-orbital area, thereby extending into the brain, and
resulting in a more widespread form such as rhino-orbital or rhino-
orbito-cerebral form.
So, we have hypothesized that a chronic local insult, such as a
chronic sinusitis, might have acted as a predisposing factor for a
possible development of Mucor infection in immunocompetent/
otherwise healthy individuals.
This speculation seems to be supported by the evidence that a
chronic sinusitis might be caused by an alteration of ﬁrst-line barrier
defense of upper airway (sinusal mucosa) caused by an impairment
of mucociliary clearance. An impairment or loss of immune defense
at the sinusal mucosa would render individuals more vulnerable to
fungal colonization.144 In addition, it has been hypothesized that
patients with chronic sinusitis have a reduction of several molecules,
such as S100 and SPINK5, members of epidermal differentiation
complex, which are necessary in maintenance of barrier function in
the upper airways and sinuses.145
The analysis of literature review has shown that even in
immunocompetent/otherwise healthy individuals mucormycosis
infection has a worldwide distribution with 35 countries
involved5–130 (Figure 2A). In Italy, it appears very rare with only
six cases reported over the last 30 years: two cases of rhino-orbito-
cerebal,5,32, and four cases of cutaneous/subcutaneous.66,112,116,127
However, adding our 5 cases to the 6 already described, despite the
rarity of this infection, Italy gained the fourth place with 11 cases,after India with 94, USA with 42 and Australia with 12, thus
rendering the rhino-orbito-cerebral form as the most represented
in Italy.
Moreover, it has been recently published an Italian survey
describing 60 cases of mucormycosis, of which 18 turned out to be
immunocompetent. This is a relevant paper, because Italy should
reach a total number of 30 immunocompetent/otherwise healthy
patients with mucormycosis.146 However, even though this is a
remarkable report, we were unable to add it to our review, because
it was impossible to determine what kind of clinical form of
mucormycosis each single patient had suffered from.
To the best of our knowledge, at least 212 cases of
mucormycosis in immunocompetent/otherwise healthy individu-
als, without underlying risk factors and/or concurrent or past
medical illnesses have been descried.5–130 Of these 212 patients
showed a predominance of the cutaneous/subcutaneous forms
with 90 patients described as regards to other forms, such as 81
rhino-orbito-cerebral, 18 genito-urinary, 10 disseminated, 7
pulmonary, 5 gastrointestinal, and 1 vascular (Table 3).
It also seems that the clinical form of mucormycosis in such
patients would be tightly related to the type of risk factor. Indeed,
M.D. Mignogna et al. / International Journal of Infectious Diseases 15 (2011) e533–e540e538as demonstrated by a previous investigation,147 the majority of
patients (73%) without any underlying risk factors, who developed
mucormycosis following burn, trauma, or surgery, presented with
the cutaneous form, whereas among patients with mucormycosis
due to other causes rather than burn, trauma, or surgery, the
cutaneous form was just represented by 28%.
Intriguingly, although inhalation appears to be the most
common route of infection with subsequent involvement of
respiratory tract, resulting in both rhino-orbito-cerebral and
pulmonary forms, the literature review has shown that in
immunocompetent/otherwise healthy patients, the most common
clinical presentation of mucormycosis turned out to be the
cutaneous/subcutaneous form (Figure 2B), following burns or
trauma with a contaminated object or soil. Considering the
ubiquitous nature of this infective agent, it is likely that in
immunocompetent patients the immunological defense of upper
airways is more capable of facing IFIs. Conversely, disseminated
forms might have been due to undiagnosed underlying risk factors,
or a delay of diagnosis or appropriate treatment.
We do not know what might have been the route of infection of
genitor-urinary form and it is also surprising to notice from
literature review how large is the number of immunocompetent/
otherwise healthy patients with this form (8.5%) (Figure 2B), as it
usually occurs as a part of disseminated form in patients with
predisposing risk factors, such as intravenous drug abuse or
corticosteroids therapy.73 Thus, further investigations are required
to better elucidate the epidemiology and pathogenesis of this
entity.73
The largest review on mucormycosis, published in 2005,
gathered 929 cases from 1885 to 2005.147 This study demonstrated
that patients with mucormycosis with no underlying condition at
the time of infection were 176 out of 929 (19%) with a mortality
rate of 35% (61 out of 176). Also, of the overall 176 patients, 87
developed mucormycosis following trauma, burns or surgery and
89 following other causes, to a total of 88 patients with cutaneous
form (50%). These data are quite similar to ours, which showed a
rate of 42.2% about the cutaneous/subcutaneous form. Conversely,
different results come from the remaining forms: indeed, in the
Roden et al.’s review, the rhino-orbito-cerebral form (including
cerebral, rhinocerebral, sinus, and sino-orbital) showed a rate of
25%, comparing with a rate of 38.2% from our review, and
gastrointestinal and pulmonary showed 9% and 8% respectively,
comparing with a rate of 2.4% and 3.3% form our review (Figure 2B).
In addition, a rising trend has been noticed, with more than half
cases (62.6%) described over last 10 years (Figure 2C). Whether this
implies a rise of Mucor infection in immunocompetent/healthy
individuals in the next decade and whether this trend may reﬂect a
rise in global poverty and difﬁculty in receiving adequate medical/
surgical treatments either in developed or developing countries is
unknown.
The fact that India turned out to be the most affected country
(Figure 2A) might be probably related to climatic, socio-economic,
scarce hygienic conditions, and, last but not least, diagnostic delay.
Indeed, a signiﬁcant proportion of the Indian population lives
below the poverty line and hence may be malnourished, which
may predispose them to more easily contract an IFI.148 Also, as
diabetes mellitus is extremely common in India, some patients
with IFI may have had undiagnosed diabetes mellitus, that is a
well-known predisposing factor.148 Conversely, in USA turned out
to be the second most common country (Figure 2A) as it is probably
due to its multiethnic background where people travel worldwide
to a greater extent, and to difﬁculty for poor persons to access
appropriate medical and/or surgical therapies.
However, we do not know whether this peculiar geographic
distribution may even reﬂect a genetic predisposition of the
inhabitants.Eventually, we have to consider that the analysis of the
literature review might present a signiﬁcant bias, as we do not
know if all the immunocompetent/otherwise healthy patients with
mucormycosis have ever been reported worldwide: many
clinicians in developed countries might have underestimated
the importance of reporting such cases rather than other clinicians
in developing countries.
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